Clinical Trials
26 trialsREVIVE
University of Chicago
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
M.D. Anderson Cancer Center
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Swiss Cancer Institute
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Duke University
TRIPL
Montefiore Medical Center
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
RAD-IO
The Netherlands Cancer Institute
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Henry Ford Health System
N-PLANC
Mayo Clinic
CECYDE
Gruppo Oncologico Italiano di Ricerca Clinica
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
LAG-MAPS
Intergroupe Francophone de Cancerologie Thoracique
META-1
UNICANCER
EMITT-1
Grey Wolf Therapeutics
HYPERBOLIC
Università Vita-Salute San Raffaele
PALACE
Fundación GECP
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mount Sinai
Dupi-Cemi
Centre hospitalier de l'Université de Montréal (CHUM)
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute